President Claudia Sheinbaum announced an investment of 21 billion pesos by pharmaceutical companies as part of Plan Mexico. The objective is to increase the production of medicines, strengthen the industry and diversify exports.
“There are more than 21 billion pesos of drug production in Mexico, also linked to clinical research. As you know, the objective of Plan Mexico is to produce more in Mexico than we consume in Mexico and also to allow us to export to other countries,” he said at the morning conference.
The Secretary of Health, David Kershenobich, highlighted that these projects encourage industrial development through national pharmaceutical production.
Announced investments
- ABBOTT: 3,500 million pesos for a new facility in Querétaro. It will generate 1,200 jobs by 2030, focused on medical devices for the diagnosis of cardiac disorders.
- Bristol Myers Squibb: 1,000 million pesos for clinical research and local manufacturing of innovative therapies. It will create 380 direct and 65 indirect jobs.
- Neolpharma Group: 750 million pesos for three pharmaceutical raw materials plants in Toluca, with a capacity of 2,300 tons per year. It will generate 250 direct and 900 indirect jobs.
- Opella: 2,300 million pesos to expand its plant in Ocoyoacac, with a new line of Enterogermina®. It seeks to convert Mexico into a regional export platform. 50 direct jobs and 450 indirect jobs.
- Vazol Farma (Kener Laboratories): 5,360 million pesos in three projects, including a biotechnology plant. They add to the 5,180 million pesos announced in July 2025. 220 direct and 550 indirect jobs.
- Liomont: 4,000 million pesos for a new oral solids plant and expansion of biotechnological injectables and vaccines in Ocoyoacac and Cuajimalpa. 370 direct and 400 indirect jobs.
- Sanofi: more than 2,000 million pesos to build an insulin plant that will cover 100% of patients. It already generates 900 direct jobs in its vaccine antigen plant.
- Bayer: reported an advance of 33% of a previous investment of 3,000 million pesos, and announced an additional 150 million pesos for 10 clinical studies in public and private institutions.
These investments reinforce the country’s health sovereignty and export capacity, generating thousands of direct and indirect jobs.




